Cjc-1295 Ipamorelin For Muscle Growth
CJC-1295 Ipamorelin for Muscle Growth
The short answer
CJC-1295 is a GHRH analog and Ipamorelin is a selective GH secretagogue; the pairing targets the growth hormone axis from two directions (Teichman et al., 2006; Raun et al., 1998).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is CJC-1295 and Ipamorelin, and why are they paired?
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog, and Ipamorelin is a selective growth-hormone secretagogue, so pairing them acts on the GH axis through two separate receptors.
CJC-1295 mimics GHRH, the natural signal that tells the pituitary to release growth hormone. In a controlled human study, CJC-1295 produced sustained increases in GH and IGF-1 after single doses, with effects measurable over multiple days (Teichman et al., 2006).
Ipamorelin works on a different pathway. It binds the ghrelin/GH-secretagogue receptor and prompts a GH pulse. In preclinical work, Ipamorelin released GH selectively, meaning it did so without the rise in cortisol and prolactin seen with some earlier secretagogues (Raun et al., 1998).
The logic behind combining them is that a GHRH analog and a secretagogue push GH release through complementary signals. That is the mechanistic rationale researchers describe. It is not the same as proof of a body-composition outcome.
Does CJC-1295 with Ipamorelin build muscle in humans?
Muscle-growth outcomes in trained humans are not established: no completed human trial demonstrates that this pairing increases lean mass in healthy resistance-trained adults.
Here is what the record actually contains. Teichman et al. (2006) measured hormone levels, GH and IGF-1, not muscle mass or strength. Raun et al. (1998) reported selective GH release in a preclinical model, again not human muscle outcomes. Neither study was designed to answer the muscle-growth question.
IGF-1 is downstream of growth hormone and is involved in tissue signaling, so a sustained IGF-1 rise is often cited as the theoretical link to lean mass. But a hormone moving in a plausible direction is a mechanism, not a result. The jump from "IGF-1 increased" to "trained humans gained muscle" has not been closed by a completed trial for this combination.
Read plainly: the human data support that these compounds affect the GH/IGF-1 axis. The human data do not support a muscle-growth claim.
What does the research report on the GH and IGF-1 axis?
Research reports that CJC-1295 sustained GH and IGF-1 elevations in humans, while Ipamorelin drove GH release selectively in preclinical models.
| Compound | Class | Reported axis effect | Source |
|---|---|---|---|
| CJC-1295 | GHRH analog | Sustained GH and IGF-1 increase after single doses | Teichman et al., 2006 |
| Ipamorelin | GH secretagogue | Selective GH release, minimal cortisol/prolactin rise | Raun et al., 1998 |
For wider context on GH-axis compounds: tesamorelin, another GHRH analog, reduced visceral adipose tissue by about 15 percent in a human trial (Falutz et al., 2007), and the oral secretagogue MK-677 raised fasting glucose and lowered insulin sensitivity in older adults (Nass et al., 2008). These are separate compounds, included only to show that GH-axis agents carry measurable metabolic effects and are studied for varied endpoints, not for a single "muscle" outcome.
What dose ranges appear in the research?
The figures below are what published research reported in its own protocols; they are context, not a recommendation, and any personal dose belongs with a qualified clinician.
| Compound | Research context | Reported dosing detail | Source |
|---|---|---|---|
| CJC-1295 | Human PK/PD study measuring GH and IGF-1 | Single subcutaneous doses evaluated for sustained hormone response | Teichman et al., 2006 |
| Ipamorelin | Preclinical GH-release model | Dose-dependent selective GH release characterized in animals | Raun et al., 1998 |
Two limits matter here. First, Teichman et al. (2006) studied a hormone response, not a training or muscle protocol, so its dosing tells you nothing about a muscle-building regimen. Second, Ipamorelin's characterized dosing comes from preclinical work (Raun et al., 1998), which does not translate directly to humans. This is why the responsible framing routes every personal-dose question to a clinician who can weigh individual health factors.
What are the honest limits of this evidence?
The evidence supports GH/IGF-1 axis activity and stops there; muscle outcomes, long-term safety in healthy adults, and this specific pairing's combined effect are not established in completed human trials.
- The pairing itself has not been tested for muscle growth in a controlled human trial.
- GH-axis compounds can carry metabolic effects: MK-677 lowered insulin sensitivity in one study (Nass et al., 2008), a reminder that GH-axis activity is not consequence-free.
- Human data on Ipamorelin's body-composition effects specifically are limited, and much characterization is preclinical (Raun et al., 1998).
- Research peptides here are for laboratory and research use, not for treating any condition.
Keep reading
Related research and verification
Cjc-1295 Ipamorelin For Muscle Growth: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. (PMID 16352683). Reported sustained GH and IGF-1 increases in a controlled human trial, hormone levels only, not muscle outcomes.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 (PMID 9849822). Reported selective GH release without a meaningful rise in cortisol or prolactin in preclinical work.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375 (PMID 18057338). Included for context that the GHRH analog tesamorelin reduced visceral adipose tissue in a human trial.
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. (PMID 18981485). Cited as a reminder that GH-axis agents can carry metabolic effects, MK-677 lowered insulin sensitivity.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.